Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.06, Zacks reports. The business had revenue of $53.19 million during the quarter, compared to analyst estimates of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.02% and a negative net margin of 8.59%. Vanda Pharmaceuticals updated its FY 2030 guidance to EPS and its FY 2025 guidance to EPS.
Vanda Pharmaceuticals Stock Down 6.0 %
NASDAQ:VNDA traded down $0.28 during trading hours on Monday, reaching $4.42. 1,978,333 shares of the stock were exchanged, compared to its average volume of 559,972. The company has a market capitalization of $257.73 million, a price-to-earnings ratio of -15.79 and a beta of 0.74. The business has a 50-day moving average of $4.61 and a two-hundred day moving average of $4.84. Vanda Pharmaceuticals has a twelve month low of $3.71 and a twelve month high of $6.75.
Wall Street Analysts Forecast Growth
VNDA has been the subject of a number of analyst reports. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, February 4th. StockNews.com began coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a "hold" rating on the stock.
Get Our Latest Analysis on Vanda Pharmaceuticals
About Vanda Pharmaceuticals
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
See Also
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
